{"id":65508,"date":"2017-09-14T15:47:43","date_gmt":"2017-09-15T01:47:43","guid":{"rendered":"http:\/\/www.hawaii.edu\/news\/?p=65508"},"modified":"2020-03-13T15:23:44","modified_gmt":"2020-03-14T01:23:44","slug":"alzheimers-disease-clinical-trials","status":"publish","type":"post","link":"https:\/\/www.hawaii.edu\/news\/2017\/09\/14\/alzheimers-disease-clinical-trials\/","title":{"rendered":"Alzheimer’s Disease clinical trial begins at UH<\/abbr> medical school"},"content":{"rendered":"Reading time: <\/span> < 1<\/span> minute<\/span><\/span>
\"\"
Beau Nakamoto<\/figcaption><\/figure>\n

A clinical trial on a drug that researchers hope will reduce inflammation in patients with Alzheimer\u2019s Disease will begin at the University of Â鶹´«Ã½<\/span> at M\u0101noa John A. Burns School of Medicine<\/a> (JABSOM).<\/p>\n

The JABSOM<\/abbr> trial involves an investigational therapy, NP001, developed by Neuraltus Pharmaceuticals<\/a>, Inc., a privately held biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases. This study aims to whether a single dose of NP001 will affect blood markers that indicate inflammation in individuals with mild-to-moderate Alzheimer\u2019s disease.<\/p>\n

Alzheimer\u2019s disease, an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, is currently ranked as the sixth leading cause of death in the United States. While the cause of the disease is unknown, there is increasing evidence that suggests neuroinflammation may play a role in disease progression. NP001, Neuraltus Pharmaceuticals\u2019 lead investigative therapy, is designed to help regulate neuroinflammation.<\/p>\n

“Although Alzheimer\u2019s disease is the most common cause of dementia, there is presently no cure for the more than five million Americans living with the disease,” said Beau Nakamoto<\/strong>, an associate professor in the Department of Medicine and principal investigator. “Given the key role inflammatory monocytes and macrophages may play in the progression of Alzheimer\u2019s disease, researching immune regulators—like NP001—is critical to understanding more about this serious and complex disease.”<\/p>\n

For the complete story, go the the John A. Burns School of Medicine website<\/a>.<\/p>\n

—By Tina Shelton<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

A clinical trial will begin on a drug that researchers hope will reduce inflammation in patients with mild-to-moderate Alzheimer\u2019s Disease.<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[30],"tags":[972,165,31,9],"class_list":["post-65508","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research","tag-alzheimers-disease","tag-health","tag-john-a-burns-school-of-medicine","tag-uh-manoa","entry","has-media"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t